Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0KNAHQ)
| ADC Name |
BL-M14D1
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
BL-M25D1; BL-M14D1
Click to Show/Hide
|
|||||
| Organization |
Systimmune (Originator)
|
|||||
| Drug Status |
Phase 1
|
|||||
| Drug-to-Antibody Ratio |
8
|
|||||
| Structure |
|
|||||
|
|
||||||
| Antibody Name |
Anti-DLL3 mAb
|
Antibody Info | ||||
| Antigen Name |
Delta-like protein 3 (DLL3)
|
Antigen Info | ||||
| Payload Name |
Ed-04
|
Payload Info | ||||
| Payload Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
Gly-Mal-Gly-Gly-Phe-Gly
|
Linker Info | ||||
| Conjugate Type |
Undisclosed
|
|||||
| Combination Type |
brengitecan
|
|||||
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
| Disease Name | Phase 1 | Phase 2 | Phase 3 | Approved |
|---|---|---|---|---|
| Lung cancer | ||||
| Merkel cell carcinoma | ||||
| Prostate cancer | ||||
| Unspecific solid tumor |